cytidine has been researched along with Cancer of Head in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, AT; Cher, GB; Hong, RL; Hong, WK; Huat, TE; Hui, EP; Juergens, R; Marur, S; Tsao, A | 1 |
| Fares, F; Napso, T | 1 |
1 trial(s) available for cytidine and Cancer of Head
| Article | Year |
|---|---|
Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cytidine; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2013 |
1 other study(ies) available for cytidine and Cancer of Head
| Article | Year |
|---|---|
Zebularine induces prolonged apoptosis effects via the caspase-3/PARP pathway in head and neck cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin-Dependent Kinase Inhibitor p21; Cytidine; Delayed-Action Preparations; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Promoter Regions, Genetic; Protein Kinases; Signal Transduction | 2014 |